In this context, the research of mutations in the HSP110 (T17) marker has been proposed as an alternative to conventional MSI testing assays since it provides better sensitivity and equal specificity in CRC [68,69] and requires the analysis of a sole quasi-monomorphic marker (Table 2). Here, HSPH1 is linked to colorectal carcinoma.